We have located links that may give you full text access.
Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study.
Radiotherapy and Oncology 2018 October
PURPOSE: To estimate the dose response relationship for submandibular gland (SMG) recovery using salivary scintigraphy in patients diagnosed with head and neck cancer treated with curative image guided chemoradiation.
MATERIAL AND METHODS: Ninety newly diagnosed head and neck cancer patients (T1-3, N0-2c, M0) treated with intensity modulated radiotherapy on a prospective clinical trial were assessed for salivary toxicity at predefined intervals using dynamic salivary scintigraphy. The SMG function was measured using salivary excretion fraction (SEF) ratios at baseline and 6 monthly. Tolerance dose (TD) 50 for submandibular gland was estimated from dose response curves.
RESULTS: The mean SEF ratio of 180 SMGs decreased at 6 months with a nadir at 12 months after treatment (SEF ratio 15%) and progressively recovered over time reaching 38% over 24 months. There was significant inverse correlation between SEF ratio and mean SMG dose at 6 months (r = -0.18, p = 0.04); 12-months (r = -0.36, p < 0.001); 18-months (r = -0.48, p < 0.001); 24-months (r = -0.42, p < 0.001); and more than 24-months (r = -0.56, p < 0.001). The estimated TD 50 values at 1 year and 2 year post treatment were 36 Gy and 44 Gy respectively with SEF ratio of ≤45% used to define severe xerostomia. For every 1 Gy reduction in mean dose below 54 Gy, there is 2-2.5% reduction in the probability of severe xerostomia.
CONCLUSION: The submandibular gland function declines after radiotherapy with a nadir at 12 months and there is incomplete recovery over time with continued improvement over 24 months. The TD 50 at 1 year and 2 year was 36 Gy and 44 Gy with a 2-2.5% reduction in the probability of severe xerostomia for every 1 Gy reduction in mean dose.
MATERIAL AND METHODS: Ninety newly diagnosed head and neck cancer patients (T1-3, N0-2c, M0) treated with intensity modulated radiotherapy on a prospective clinical trial were assessed for salivary toxicity at predefined intervals using dynamic salivary scintigraphy. The SMG function was measured using salivary excretion fraction (SEF) ratios at baseline and 6 monthly. Tolerance dose (TD) 50 for submandibular gland was estimated from dose response curves.
RESULTS: The mean SEF ratio of 180 SMGs decreased at 6 months with a nadir at 12 months after treatment (SEF ratio 15%) and progressively recovered over time reaching 38% over 24 months. There was significant inverse correlation between SEF ratio and mean SMG dose at 6 months (r = -0.18, p = 0.04); 12-months (r = -0.36, p < 0.001); 18-months (r = -0.48, p < 0.001); 24-months (r = -0.42, p < 0.001); and more than 24-months (r = -0.56, p < 0.001). The estimated TD 50 values at 1 year and 2 year post treatment were 36 Gy and 44 Gy respectively with SEF ratio of ≤45% used to define severe xerostomia. For every 1 Gy reduction in mean dose below 54 Gy, there is 2-2.5% reduction in the probability of severe xerostomia.
CONCLUSION: The submandibular gland function declines after radiotherapy with a nadir at 12 months and there is incomplete recovery over time with continued improvement over 24 months. The TD 50 at 1 year and 2 year was 36 Gy and 44 Gy with a 2-2.5% reduction in the probability of severe xerostomia for every 1 Gy reduction in mean dose.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app